Key result
Atorvastatin was more effective than simvastatin-based therapies in achieving target LDL < 3.5 mmol/l in patients with severe hyperlipidaemia, but increased side effects.
Why the study?
Does atorvastatin improve lipid profiles compared to simvastatin-based therapies in patients with severe familial hyperlipidaemia?
Observational (n=201)
Does atorvastatin improve lipid profiles compared to simvastatin-based therapies in patients with severe familial hyperlipidaemia?
Atorvastatin is more effective than simvastatin-based therapies in achieving LDL targets in severe familial hyperlipidaemia, though potentially with an increase in side effects.
Answers are grounded in this paper and cite their sources.
May support atorvastatin preference for LDL targets in severe hyperlipidaemia; observational data leave open randomized confirmation amid side-effect trade-offs.
We compared atorvastatin with simvastatin-based therapies in a prospective observational study of 201 patients with severe hyperlipidaemia. Atorvastatin 10 mg therapy was substituted for simvastatin 20 mg, 20 mg for 40 mg, 40 mg for simvastatin 40 mg plus resin, and 80 mg for simvastatin-fibrate-resin therapy. Lipid and safety profiles were assessed. Atorvastatin reduced total cholesterol by 31 +/- 11-40 +/- 14% vs. 25 +/- 12-31 +/- 11%; LDL by 38 +/- 16-45 +/- 18% vs. 31 +/- 18-39 +/- 18% and geometric mean triglycerides by 29.3-37.3% vs. 16.6-24.8%, but reduced HDL 11% +/- 47% at 80 mg compared with a 16% +/- 34% increase with simvastatin-based therapy. Target LDL < 3.5 mmol/l was achieved more often with atorvastatin (63% vs. 50%; p < 0.001). Atorvastatin increased geometric mean fibrinogen by 12-20% vs. a 0-6% fall with simvastatin (p << 0.001). Side effects were noted in 10-36% of patients, including one case of rhabdomyolysis, and 36% discontinued therapy. These data suggest that atorvastatin is more effective than current simvastatin-based therapies in achieving treatment targets in patients with familial hypercholesterolaemia but at the expense of a possible increase in side-effects. This issue needs further study in randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Anthony S. Wierzbicki (1999) conducted an observational in Severe hyperlipidaemia (n=201). Atorvastatin vs. Simvastatin-based therapies was evaluated on Target LDL < 3.5 mmol/l (p=< 0.001). Atorvastatin was more effective than simvastatin-based therapies in achieving target LDL < 3.5 mmol/l in patients with severe hyperlipidaemia, but increased side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: